Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
NanoString Technologies's peak revenue was $145.1M in 2021. The peak quarterly revenue was $48.1M in 2023(q3).
NanoString Technologies's revenue increased from $23.0m in 2012 to $127.3M currently. That's a 453.96% change in annual revenue.
| Fiscal year / year | NanoString Technologies revenue |
|---|---|
| 2012 | $23.0M |
| 2013 | $31.4M |
| 2014 | $47.6M |
| 2015 | $62.7M |
| 2016 | $86.5M |
| 2017 | $114.9M |
| 2018 | $106.7M |
| 2019 | $125.6M |
| 2020 | $117.3M |
| 2021 | $145.1M |
| 2022 | $127.3M |
Rate NanoString Technologies' financial transparency
NanoString Technologies saw the greatest revenue growth in 2014, when revenue increased by 51.56%.
NanoString Technologies had the lowest revenue growth in 2022, when revenue changed by -12.28%.
| Year | NanoString Technologies growth |
|---|---|
| 2013 | 37%↑ |
| 2014 | 52%↑ |
| 2015 | 32%↑ |
| 2016 | 38%↑ |
| 2017 | 33%↑ |
| 2018 | -7%↓ |
| 2019 | 18%↑ |
| 2020 | -7%↓ |
| 2021 | 24%↑ |
| 2022 | -12%↓ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | $7.2M | $8.4M | $10.1M |
| 2014 | $8.8M | $10.9M | $12.3M | $15.6M |
| 2015 | $11.6M | $13.1M | $15.7M | $22.3M |
| 2016 | $14.7M | $22.6M | $23.9M | $25.2M |
| 2017 | $18.1M | $34.6M | $27.0M | $35.2M |
| 2018 | $23.1M | $25.0M | $28.6M | $30.0M |
| 2019 | $27.7M | $30.3M | $30.6M | $36.9M |
| 2020 | $26.6M | $22.6M | $31.8M | $36.3M |
| 2021 | $31.6M | $33.9M | $37.2M | $42.5M |
| 2022 | $31.1M | $32.2M | $29.5M | $34.4M |
| 2023 | $35.8M | $44.2M | $48.1M | - |
Do you work at NanoString Technologies?
Is NanoString Technologies transparent about its revenue structure?
| CEO | Robert Bradley Gray |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 270 |
| Date Founded | 2003 |
| Headquarters | Seattle, Washington |
| Number of Locations | 1 |
| Revenue | $127.3M |
| Net Income | -$159,543,000 |
| Gross Proft | $61.8M (2022) |
| PE Ratio | -4.32 |
| Tax Rate | -0.0% |
| Market Capitalization | $689.4M |
| Total Assets | $353,412,000 |
| Ticker | NSTG |
NanoString Technologies received early financing of $3.8M on 2005-04-27.
| Series | Round size | Date |
|---|---|---|
| Series A | $3.8M | 04/2005 |
| Series B | $8.5M | 06/2007 |
| Series C | $30M | 06/2009 |
| Series Unknown | $15M | 02/2010 |
| Debt Financing | $2.5M | 06/2011 |
| Series D | $20M | 11/2011 |
| Debt Financing | $15M | 04/2012 |
| Series E | $15.3M | 12/2012 |
| Series Unknown | $150K | 05/2013 |
| Post Ipo Debt | $45M | 04/2014 |
| Post Ipo Equity | $56M | 06/2017 |
| Post Ipo Equity | $46.8M | 07/2018 |
| Post Ipo Equity | $68.3M | 03/2019 |
| Post Ipo Debt | $175M | 03/2020 |
| Post Ipo Equity | $230M | 10/2020 |
| Investors | Security type |
|---|---|
| OVP Venture Partners | Series A |
| Threshold Ventures | Series A |
| OVP Venture Partners | Series B |
| Threshold Ventures | Series B |
| CLARUS VENTURES LLC | Series C |
| CLARUS VENTURES LLC | Series Unknown |
| CLARUS VENTURES LLC | Series D |
| LYSOSOMAL THERAPEUTICS INC | Series D |
| GE Healthcare | Series D |
| BioMed Ventures | Series D |
| Threshold Ventures | Series D |
| OVP Venture Partners | Series D |
| Oxford Finance LLC | Debt Financing |
| Silicon Valley Bank | Debt Financing |
| Morgan Stanley Expansion Capital | Series E |
| CLARUS VENTURES LLC | Series E |
| ALLIANCEBERNSTEIN L.P. | Series E |
| GE Ventures | Series E |
| BioMed Ventures | Series E |
| OVP Venture Partners | Series E |
| Threshold Ventures | Series E |
| CLARUS VENTURES LLC | Series Unknown |
| Accelerator Corp | Series Unknown |
| Threshold Ventures | Series Unknown |
| CRG LP | Post Ipo Debt |
NanoString Technologies's top competitor, Merck, earned an annual revenue of $64.2B.
NanoString Technologies's smallest competitor is ZymoGenetics with revenue of $27.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | $85,008 | $2.0B | 900 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 589 |
| Regeneron | $85,589 | $14.2B | 9,123 | 352 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| ZymoGenetics | $90,249 | $27.0M | 200 | - |
| Merck | $90,328 | $64.2B | 74,000 | 1,335 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 195 |
| Cubist Pharmaceuticals | $91,725 | $926.4M | 873 | - |
| Quidel | $71,489 | $1.7B | 1,500 | - |
| Medivation | $94,135 | $1.0B | 628 | - |
Zippia gives an in-depth look into the details of NanoString Technologies, including salaries, political affiliations, employee data, and more, in order to inform job seekers about NanoString Technologies. The employee data is based on information from people who have self-reported their past or current employments at NanoString Technologies. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by NanoString Technologies. The data presented on this page does not represent the view of NanoString Technologies and its employees or that of Zippia.
NanoString Technologies may also be known as or be related to NANOSTRING TECHNOLOGIES INC, NanoString Technologies, NanoString Technologies Inc, NanoString Technologies, Inc. and Nanostring Technologies, Inc.